Immunotherapeutic interventions of triple negative breast cancer
Abstract Triple Negative Breast Cancer (TNBC) is a highly heterogeneous subtype of breast
cancer that lacks the expression of oestrogen receptors, progesterone receptors and human …
cancer that lacks the expression of oestrogen receptors, progesterone receptors and human …
PARP inhibitors in the treatment of triple-negative breast cancer
JJJ Geenen, SC Linn, JH Beijnen… - Clinical …, 2018 - Springer
Breast cancer is a heterogeneous disease, manifesting in a broad differentiation in
phenotypes and morphologic profiles, resulting in variable clinical behavior. Between 10 …
phenotypes and morphologic profiles, resulting in variable clinical behavior. Between 10 …
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance
SJ Pettitt, DB Krastev, I Brandsma, A Dréan… - Nature …, 2018 - nature.com
Although PARP inhibitors (PARPi) target homologous recombination defective tumours,
drug resistance frequently emerges, often via poorly understood mechanisms. Here, using …
drug resistance frequently emerges, often via poorly understood mechanisms. Here, using …
CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer
SF Johnson, C Cruz, AK Greifenberg, S Dust… - Cell reports, 2016 - cell.com
Although poly (ADP-ribose) polymerase (PARP) inhibitors are active in homologous
recombination (HR)-deficient cancers, their utility is limited by acquired resistance after …
recombination (HR)-deficient cancers, their utility is limited by acquired resistance after …
The Fanconi anemia pathway protects genome integrity from R-loops
ML García-Rubio, C Pérez-Calero, SI Barroso… - PLoS …, 2015 - journals.plos.org
Co-transcriptional RNA-DNA hybrids (R loops) cause genome instability. To prevent harmful
R loop accumulation, cells have evolved specific eukaryotic factors, one being the BRCA2 …
R loop accumulation, cells have evolved specific eukaryotic factors, one being the BRCA2 …
BRCA1 mutation-specific responses to 53BP1 loss-induced homologous recombination and PARP inhibitor resistance
BRCA1 functions in homologous recombination (HR) both up-and downstream of DNA end
resection. However, in cells with 53BP1 gene knockout (KO), BRCA1 is dispensable for the …
resection. However, in cells with 53BP1 gene knockout (KO), BRCA1 is dispensable for the …
FAM 35A associates with REV 7 and modulates DNA damage responses of normal and BRCA 1‐defective cells
To exploit vulnerabilities of tumors, it is urgent to identify associated defects in genome
maintenance. One unsolved problem is the mechanism of regulation of DNA double‐strand …
maintenance. One unsolved problem is the mechanism of regulation of DNA double‐strand …
BRCA1 mutations in cancer: coordinating deficiencies in homologous recombination with tumorigenesis
JJ Krais, N Johnson - Cancer research, 2020 - AACR
Cancers that arise from BRCA1 germline mutations are deficient for homologous
recombination (HR) DNA repair and are sensitive to DNA-damaging agents such as …
recombination (HR) DNA repair and are sensitive to DNA-damaging agents such as …
SETDB1, HP1 and SUV39 promote repositioning of 53BP1 to extend resection during homologous recombination in G2 cells
M Alagoz, Y Katsuki, H Ogiwara, T Ogi… - Nucleic acids …, 2015 - academic.oup.com
Recent studies have shown that homologous recombination (HR) requires chromatin
repression as well as relaxation at DNA double strand breaks (DSBs). HP1 and SUV39H1/2 …
repression as well as relaxation at DNA double strand breaks (DSBs). HP1 and SUV39H1/2 …
PD-1/PD-L1 axis importance and tumor microenvironment immune cells
Triple-negative breast cancer (TNBC) is heterogeneous cancer with poor prognosis among
the other breast tumors. Rapid recurrence and increased progression rate could be reasons …
the other breast tumors. Rapid recurrence and increased progression rate could be reasons …